Amino-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Testing - Recent Lessons Learned

Login or register to view PDF.

The use of natriuretic peptide testing has dramatically risen recently, in recognition of the value of these blood tests for assisting in the evaluation of patients with suspected heart failure (HF). B-type natriuretic peptide (BNP) is formed as a consequence of production of a 108-amino-acid precursor peptide that is synthesized within the cardiomyocyte; this 'pro-BNP108' is subsequently cleaved at the time of release of the peptide by the cardiomyocyte into two fragments: the 32-aminoacid BNP, and the 76-amino-acid amino-terminal portion (NT-proBNP). BNP has numerous biologic effects in the body, including induction of diuresis and natriuresis, vasodilation, and downregulation of the renin-angiotensin-aldosterone system. These effects bespeak of the potential usefulness of measurement of BNP or NT-proBNP in disease states such as HF.


The first US Food and Drug Administration (FDA)- approved BNP assay became available in 2001. Subsequently, automated assays for NT-proBNP received approval in 2002 and, since then, testing for the natriuretic peptides has been shown to be exceptionally useful for numerous clinical applications, including the evaluation of the patient complaining of dyspnea, as elevated concentrations of these markers have been shown to be present in patients with acute HF, a diagnosis that is typically difficult to secure using standard clinical methods.

Since the earliest experiences with BNP and NT-proBNP, much has been learned about the utility of these tests for evaluation of patients with suspected or proven HF.

Comparing BNP with NT-proBNP
Analytical Differences
As would be expected, the analytical methods for testing both BNP and NT-proBNP differ considerably, and as such it is not surprising that considerable differences between the two markers exist with respect to optimal methods for their testing. It has been shown that recoverable levels of BNP fall rapidly after phlebotomy,1 which likely reflects on-going activity of neutral endopeptidases in the blood sample or activation of the kallikrein system in the tube within which the blood sample is collected.2 Indeed, a recent study using exquisitely accurate mass spectral techniques actually demonstrated that among HF patients with extremely high concentrations of 'BNP32'(as assessed by a point-ofcare immunoassay for the marker), no detectable intact BNP actually existed in the samples. This disturbing finding raises the concern that what is actually measured by BNP methods is a mixture of varying chain lengths of BNP, as well as potentially other cross-reactive species from the natriuretic peptide family of markers. In contrast, NT-proBNP is remarkably stable after release, and the methods for its measurement are highly precise another major problem for several methods of BNP measurement.
Clinical Differences
In general, the clinical information that is gained by measurement of either BNP or NT-proBNP is largely similar; results of head-to-head comparisons of the markers demonstrate similar utilities in unselected populations of patients with suspected HF. Some noteworthy differences between BNP and NT-proBNP do exist, however.

In head-to-head comparisons, while both BNP and NTproBNP had similar sensitivity and specificity for evaluation of symptomatic patients, Mueller and colleagues demonstrated that NT-proBNP had superior sensitivity to BNP for the detection of those patients with asymptomatic left ventricular (LV) dysfunction. This has serious ramifications, as the detection of patients with asymptomatic or early forms of HF has recently been emphasized by the American Heart Association (AHA). Furthermore, recent data suggest that up to 21% of symptomatic patients with established chronic HF may demonstrate BNP values below 100pg/ml, currently the only cut-off identified for use for BNP (which was based on data from acutely dyspneic patients in the emergency department (ED) setting). Indeed, a source of concern is that no optimal cut-off for use of BNP in office-based evaluation has been established for the identification of asymptomatic structural heart disease or longitudinal evaluation of patients with established HF. For NTproBNP, clinical studies demonstrate significant utility of a cut-off of 125pg/ml for patients <75 years of age and 450pg/ml for patients =75 years of age for the out-patient evaluation of patients with suspected HF (see Table 1)./>/>/>/>/>/>/>/>/>/>


  1. Yeo K T, Wu A H, Apple F S, et al., ├óÔé¼┼øMulticenter evaluation of the Roche NT├óÔé¼ÔÇ£proBNP assay and comparison to the Biosite Triage BNP assay├óÔé¼┼Ñ, Clin Chim Acta (2003);338(1├óÔé¼ÔÇ£2): pp. 107├óÔé¼ÔÇ£115.
  2. Shimizu H, Aono K, Masuta K, et al., ├óÔé¼┼øDegradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system├óÔé¼┼Ñ, Clin Chim Acta (2001);305(1├óÔé¼ÔÇ£2): pp. 181├óÔé¼ÔÇ£186.
  3. Hawkridge A M, Heublein, D M, Bergen H R 3rd, et al., ├óÔé¼┼øQuantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP├óÔé¼ÔÇ£32) in severe human heart failure├óÔé¼┼Ñ, Proc Natl Acad Sci U S A (2005);102(48): pp. 17442├óÔé¼ÔÇ£17447.
  4. Lainchbury J G, Campbell E, Frampton C M, et al., ├óÔé¼┼øBrain natriuretic peptide and n├óÔé¼ÔÇ£terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath├óÔé¼┼Ñ, J Am Coll Cardiol (2003);42(4): pp. 728├óÔé¼ÔÇ£735.
  5. Mueller T, Gegenhuber A, Poelz W, et al., ├óÔé¼┼øHead├óÔé¼ÔÇ£to├óÔé¼ÔÇ£head comparison of the diagnostic utility of BNP and NT├óÔé¼ÔÇ£proBNP in symptomatic and asymptomatic structural heart disease├óÔé¼┼Ñ, Clin Chim Acta (2004);341(1├óÔé¼ÔÇ£2): pp. 41├óÔé¼ÔÇ£48.
  6. Mueller T, Gegenhuber A, Poelz W, et al., ├óÔé¼┼øDiagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure├óÔé¼┼Ñ, Heart (2005);91(5): pp. 606├óÔé¼ÔÇ£612.
  7. Hunt S A, Abraham W T, Chin M H, et al., ├óÔé¼┼øACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society├óÔé¼┼Ñ, Circulation (2005);112(12): pp. e154├óÔé¼ÔÇ£e235.
  8. Tang W H, Girod J P, Lee M J, et al., ├óÔé¼┼øPlasma B├óÔé¼ÔÇ£type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure├óÔé¼┼Ñ, Circulation (2003);108(24): pp. 2964├óÔé¼ÔÇ£2966.
  9. Maisel A S, McCord J, Nowak R M, et al., ├óÔé¼┼øBedside B├óÔé¼ÔÇ£Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study├óÔé¼┼Ñ, J Am Coll Cardiol (2003);41(11): pp. 2010├óÔé¼ÔÇ£2017.
  10. O™Donoghue M, Chen A, Baggish A L, et al., ├óÔé¼┼øThe effects of ejection fraction on N├óÔé¼ÔÇ£terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study├óÔé¼┼Ñ, J Card Fail (2005);11(5 Suppl): pp. S9├óÔé¼ÔÇ£S14.
  11. Januzzi J L Jr, Camargo C A, Anwaruddin S, et al., ├óÔé¼┼øThe N├óÔé¼ÔÇ£terminal Pro├óÔé¼ÔÇ£BNP investigation of dyspnea in the emergency department (PRIDE) study├óÔé¼┼Ñ, Am J Cardiol (2005);95(8): pp. 948├óÔé¼ÔÇ£954.
  12. Januzzi J L, van Kimmenade R, Lainchbury J, et al., ├óÔé¼┼øNT├óÔé¼ÔÇ£proBNP testing for diagnosis and short├óÔé¼ÔÇ£term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT├óÔé¼ÔÇ£proBNP Study├óÔé¼┼Ñ, Eur Heart J (2006);27(3): pp. 330├óÔé¼ÔÇ£337.
  13. McCullough P A, Nowak R M, McCord J, et al., ├óÔé¼┼øB├óÔé¼ÔÇ£type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study├óÔé¼┼Ñ, Circulation (2002);106(4): pp. 416├óÔé¼ÔÇ£422.
  14. Anwaruddin S, Lloyd├óÔé¼ÔÇ£Jones D M, Baggish A, et al., ├óÔé¼┼øRenal function, congestive heart failure, and amino├óÔé¼ÔÇ£terminal pro├óÔé¼ÔÇ£brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study├óÔé¼┼Ñ, J Am Coll Cardiol (2006);47(1): pp. 91├óÔé¼ÔÇ£97.
  15. James S K, Lindahl B, Siegbahn A, et al., ├óÔé¼┼øN├óÔé¼ÔÇ£terminal pro├óÔé¼ÔÇ£brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)├óÔé¼ÔÇ£IV substudy├óÔé¼┼Ñ, Circulation (2003);108(3): pp. 275├óÔé¼ÔÇ£281.
  16. Jernberg T, Lindahl B, Siegbahn A, et al., ├óÔé¼┼øN├óÔé¼ÔÇ£terminal pro├óÔé¼ÔÇ£brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease├óÔé¼┼Ñ, J Am Coll Cardiol (2003);42(11): pp. 1909├óÔé¼ÔÇ£1916.
  17. Heeschen C, Hamm C W, Mitrovic V, et al., ├óÔé¼┼øN├óÔé¼ÔÇ£terminal pro├óÔé¼ÔÇ£B├óÔé¼ÔÇ£type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes├óÔé¼┼Ñ, Circulation (2004);110(20): pp. 3206├óÔé¼ÔÇ£3012.
  18. Kucher N, Printzen G, Doernhoefer T et al., ├óÔé¼┼øLow pro├óÔé¼ÔÇ£brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism├óÔé¼┼Ñ, Circulation (2003);107(12): pp. 1576├óÔé¼ÔÇ£1578.
  19. Binder L, Pieske B, Olschewski M, et al., ├óÔé¼┼øN├óÔé¼ÔÇ£terminal pro├óÔé¼ÔÇ£brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism├óÔé¼┼Ñ, Circulation (2005);112(11): pp. 1573├óÔé¼ÔÇ£1579.
  20. Januzzi J L Jr, Sakhuja R, O™Donoghue M, et al., ├óÔé¼┼øUtility of amino├óÔé¼ÔÇ£terminal pro├óÔé¼ÔÇ£brain natriuretic peptide testing for prediction of 1├óÔé¼ÔÇ£year mortality in patients with dyspnea treated in the emergency department├óÔé¼┼Ñ, Arch Intern Med (2006);166(3): pp. 315├óÔé¼ÔÇ£320.
  21. Baggish A, Cameron R, Anwaruddin S, et al., ├óÔé¼┼øA clinical and biochemical critical pathway for the evaluation of patients with suspected acute congestive heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) algorithm├óÔé¼┼Ñ, Crit Pathways in Cardiol (2004);3: pp. 171├óÔé¼ÔÇ£176.
  22. Bettencourt P, Azevedo A, Pimenta J, et al., ├óÔé¼┼øN├óÔé¼ÔÇ£terminal├óÔé¼ÔÇ£pro├óÔé¼ÔÇ£brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients├óÔé¼┼Ñ, Circulation (2004);110(15): pp. 2168├óÔé¼ÔÇ£2174.